Trial
NCT03785184
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
Genentech, Inc.; Celgene Corporation
Condition
Multiple Myeloma
Intervention
venetoclax
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-28